SELLAS Life Sciences (SLS) EBT Margin (2012 - 2022)
SELLAS Life Sciences' (SLS) quarterly EBT Margin came in at 1683.5% in Q1 2022, down 164236.0% year-on-year from N/an in Q1 2021, and down 602.54% on a QoQ basis from 239.63% in Q2 2021.
SELLAS Life Sciences (SLS) EBT Margin (2012 - 2022) Analysis & Trends
SELLAS Life Sciences (SLS) has 7 years of EBT Margin data on file, last reported at 1683.5% in Q1 2022.
- On a quarterly basis, EBT Margin fell 164236.0% year-over-year to 1683.5% in Q1 2022; TTM through Dec 2022 was 4245.0%, a 390692.0% decrease from a year earlier, with the FY2022 full-year figure at 4130.1%, down 385463.0% from the prior year.
- EBT Margin for Q1 2022 stood at 1683.5%, down from 239.63% in the prior quarter.
- Over the last five years, EBT Margin for SLS reached as high as 41.14% in Q1 2021 and fell as low as 1683.5% in Q1 2022.
- Historically, EBT Margin has averaged 547.11% across 3 years, with a median of 231.89% in 2020.
- On a YoY basis, EBT Margin climbed as much as 164236 bps in 2022 and fell as far as 164236 bps in 2022.
- Year by year, EBT Margin stood at 224.16% in 2020, then declined by 7 bps to 239.63% in 2021, then sank by 603 bps to 1683.5% in 2022.
- Per Business Quant data, the three most recent EBT Margin figures were 1683.5% in Q1 2022, 239.63% in Q2 2021, and 41.14% in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 17.13% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 33.74% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | SELLAS Life Sciences | 1.96 Bn | 1.96 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | -1,683.50% |
| Jun 30, 2021 | -239.63% |
| Mar 31, 2021 | -41.14% |
| Dec 31, 2020 | -224.16% |
| Jun 30, 2015 | -294.94% |
| Mar 31, 2015 | -341.45% |
| Dec 31, 2014 | -285.79% |
| Sep 30, 2014 | -748.02% |
| Jun 30, 2014 | -947.70% |
| Mar 31, 2014 | -716.38% |
| Dec 31, 2013 | -1,315.68% |
| Sep 30, 2013 | -501.73% |
| Jun 30, 2013 | -345.60% |
| Mar 31, 2013 | -554.76% |
| Dec 31, 2012 | 410.51% |
| Sep 30, 2012 | -535.13% |